The FGFR4 deficiency causes increases in systemic factors, including the adipocyte-targeting hepatic stress hormone FGF21 and ileal FGF15 (human FGF19), accompanied by increases in the tumor-suppressive adipokine adiponectin and decreases in tumor-promoting adipokines IGF-1 and TIMP1 that are controlled by anti-obesogenic FGF21. This evidence concerns the gene FGF21 and neoplasm.